Show simple item record

Article

dc.creatorConejo Gonzalo, Mª Carmenes
dc.creatorPascual Hernández, Álvaroes
dc.creatorOtero, Jesúses
dc.creatorOrtega, Adrianaes
dc.creatorBartolomé, Rosa M.es
dc.creatorBou, Germánes
dc.creatorFernández Martínez, Martaes
dc.creatorGonzález López, Juan Josées
dc.date.accessioned2017-09-28T16:41:12Z
dc.date.available2017-09-28T16:41:12Z
dc.date.issued2015-06-01
dc.identifier.citationConejo Gonzalo, M.C., Pascual Hernández, Á., Otero, J., Ortega, A., Bartolomé, R.M., Bou, G.,...,González López, J.J. (2015). Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrobial Agents and Chemotherapy, 59 (6), 3406-3412.
dc.identifier.issn0066-4804 (impreso)es
dc.identifier.issn1098-6596 (electrónico)es
dc.identifier.urihttp://hdl.handle.net/11441/64854
dc.description.abstractThe aim of this study was to determine the impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2013 by describing the prevalence, dissemination, and geographic distribution of CPE clones, and their population structure and antibiotic susceptibility. From February 2013 to May 2013, 83 hospitals (about 40,000 hospital beds) prospectively collected nonduplicate Enterobacteriaceae using the screening cutoff recommended by EUCAST. Carbapenemase characterization was performed by phenotypic methods and confirmed by PCR and sequencing. Multilocus sequencing types (MLST) were determined for Klebsiella pneumoniae and Escherichia coli. A total of 702 Enterobacteriaceae isolates met the inclusion criteria; 379 (54%) were CPE. OXA-48 (71.5%) and VIM-1 (25.3%) were the most frequent carbapenemases, and K. pneumoniae (74.4%), Enterobacter cloacae (10.3%), and E. coli (8.4%) were the species most affected. Susceptibility to colistin, amikacin, and meropenem was 95.5%, 81.3%, and 74.7%, respectively. The most prevalent sequence types (STs) were ST11 and ST405 for K. pneumoniae and ST131 for E. coli. Forty-five (54.1%) of the hospitals had at least one CPE case. For K. pneumoniae, ST11/OXA-48, ST15/OXA-48, ST405/OXA-48, and ST11/VIM-1 were detected in two or more Spanish provinces. ST11 isolates carried four carbapenemases (VIM-1, OXA-48, KPC-2, and OXA-245), but ST405 isolates carried OXA-48 only. A wide interregional spread of CPE in Spain was observed, mainly due to a few successful clones of OXA-48-producing K. pneumoniae (e.g., ST11 and ST405). The dissemination of OXA-48-producing E. coli is a new finding of public health concern. According to the susceptibilities determined in vitro, most of the CPE (94.5%) had three or more options for antibiotic treatmentes
dc.description.sponsorshipFondo de Investigación Sanitaria PI12/01242es
dc.description.sponsorshipGeneral de Redes y Centros de Investigación Cooperativa y Ministerio de Economía y Competitividad y Spanish Network for Research in Infectious Diseases REIPI RD12/0015es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherAmerican Society for Microbiologyes
dc.relation.ispartofAntimicrobial Agents and Chemotherapy, 59 (6), 3406-3412.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleProspective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenemes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Microbiologíaes
dc.relation.projectIDPI12/01242es
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/RD12/0015es
dc.relation.publisherversionhttp://dx.doi.org/10.1128/AAC.00086-15es
dc.identifier.doi10.1128/AAC.00086-15es
idus.format.extent7 p.es
dc.journaltitleAntimicrobial Agents and Chemotherapyes
dc.publication.volumen59es
dc.publication.issue6es
dc.publication.initialPage3406es
dc.publication.endPage3412es
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Economía y Competitividad (MINECO). España

FilesSizeFormatViewDescription
Prospective multicenter study ...805.0KbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional